Menu Search
Equities

Haoxi Health Technology Ltd

HAO:NAQ

Haoxi Health Technology Ltd

Actions
TechnologyTechnology
  • Price (USD)0.1919
  • Today's Change-0.011 / -5.61%
  • Shares traded1.75m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Haoxi Health Technology Ltd grew revenues 71.88% from 28.23m to 48.52m while net income improved 33.20% from 969.75k to 1.29m.
Gross margin5.67%
Net profit margin2.66%
Operating margin3.54%
Return on assets12.94%
Return on equity20.12%
Return on investment19.10%
More ▼

Cash flow in USDView more

In 2024, Haoxi Health Technology Ltd increased its cash reserves by 453.17%, or 5.45m. Cash Flow from Financing totalled 9.32m or 19.22% of revenues. In addition the company used 747.58k for operations while cash used for investing totalled 3.13m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.3496
Tangible book value per share0.3496
More ▼

Balance sheet in USDView more

Haoxi Health Technology Ltd appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 6.66m. In fact, 0.65% of the value of Haoxi Health Technology Ltd shares can be attributed to this cash.
Current ratio3.98
Quick ratio--
Total debt/total equity0.1007
Total debt/total capital0.0915
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 38.76%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		38.76
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.